Moderna's Q2 2026 update confirms stabilization in revenues predominantly from COVID-19 vaccines such as Spikevax and mNEXSPIKE amid weakening RSV sales and a challenging norovirus vaccine trial. The company relies on its proprietary mRNA platform, combining innovative lipid nanoparticle delivery and global manufacturing, to push forward a robust pipeline in oncology, infectious diseases, and rare diseases. While regulatory review of seasonal flu vaccine candidates is underway, multiple patent litigations mark ongoing risks. Financially, Moderna maintains solid liquidity with modest leverage but faces margin pressure as R&D investment intensifies to sustain next-generation product innovation beyond pandemic-era vaccines.